Investigational drug · Phase 3
BLI5100
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Erosive Esophagitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "BLI5100"
First trial start
2022
Oct 30, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BLI5100", any sponsor or status.
Conditions studied
As listed on its trial records.
- Erosive Esophagitis
Approved drugs for the same conditions: Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "BLI5100" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive EsophagitisPivotal-lookingCompleted
Braintree LaboratoriesIndustry
NCT05587309 · 1,250 participants · Start Oct 30, 2022 · Primary completion Jun 16, 2025
Drug: BLI5100; PPI Control · For: Erosive Esophagitis
Sites: Homewood, Alabama; Huntsville, Alabama; Peoria, Arizona · 122 sites in all
- A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux DiseasePivotal-lookingCompleted
Braintree LaboratoriesIndustry
NCT05587322 · 788 participants · Start Sep 6, 2022 · Primary completion Oct 13, 2023
Drug: BLI5100; Placebo · For: Non-erosive Reflux Disease
Sites: Huntsville, Alabama; Peoria, Arizona; Phoenix, Arizona · 112 sites in all
- A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux DiseasePivotal-lookingCompleted
Braintree LaboratoriesIndustry
NCT05890001 · 400 participants · Start Apr 5, 2023 · Primary completion Oct 8, 2024
Drug: BLI5100 · For: Non-erosive Reflux Disease; Erosive Esophagitis
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 60 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.